Basic Informations

C.V

C.V               

Name :Raghda Roshdy Sayed Hussein

Age : 30 years

Address:Al Gawhara Tower, El Rawdaa Street, Beni-Suef,Egypt

Social : Married and having 2 childern

Phone Number:00201010647666

E-mail: raghda. hussien@pharm.bsu.edu.eg

Profession : Assisstant Lecturer of Clinical Pharmacy at Faculty of Pharmacy,Beni-Suef University

EDUCATION

1.                 Master of Clinical Pharmacy, October 2012

2.                 Diploma of Clinical Pharmacy from Beni-Suef University, May 2009(Excellent grade).

3.                 Bachelor of Pharmaceutical Sciences,May2007 (Excellent with the grade of Honor), Beni-Suef University, Egypt

PROFESSIONAL EXPERIENCE

1.                 Demonstrator at Clinical Pharmacy department at faculty of pharmacy, beni-Suef University, Egypt from 2008 t0 2012

2.                 Assistant Lecturer at Clinical Pharmacy department at faculty of pharmacy, beni-Suef University, Egypt from 2012up to now

3.                 Going on the laboratory work up of in-vivo and in-vitro measurement of the dose emission characters from Ventoline metered dose inhaler.

4.                 Participating at the Quality Unit at our faculty of Pharmacy as ???? ????.

5.                 Participating in another scientific project of the role of community pharmacist during prescribing the non-steroidal anti-inflammatory drugs for the elderly patients.

6.                 Participating in the scientific research of comparison of upper gastrointestinal complications of non-steroidal anti-inflammatory drugs in elderly patients.

7.                 Working on programme of statistics called SPSS version 16.

8.                 Conducting Master thesis on Effect of Antiepileptic Drugs on Liver Enzymes.

9.                 Passing International Computer Driving License Tests.

10.            Passing Local Toefel Test with high score and passing for International Toefel Test with score 71.

11.            Passing IELTS with score of 6.

12.            Supervision of the clinical pharmacy scientific projects of the students.

13.            Conducting power point presentations of the courses of clinical pharmacy.

14.            Ensures the full implementation of ideal teaching rules and techniques through the usage of mind mapping.

15.             Follow the standard code of ethics of my faculty and my university through making ethical approvals for each clinical study.

16.             Participating in the quality affairs of our faculty to be a part from a team aiming to increase the ranking and scientific level of our faculty.

PUBLICATIONS

1.                 Publication of paper of master study at Beni-Suef University Journal of Applied Sciences (BUJA) , 2012.

2.                 Publication of poster of Effect of Dosing Rate and Duration of Therapy of Antiepileptic Drugs on Liver Enzymes at international conference of Advanced Basics& Applied Sciences (ABAS) , 2012.

3.                  Publication of paper of Upper gastrointestinal complications of Non-Steroidal Anti-inflammatory Drugs at medicine science journal, 2013.

4.                  Publication of paper of In-vitro characterization of the aerosolized dose during non-invasive ventilation, 2015.

MAJOR TRAINING COURSES

1.                 Training on molecular biology during a workshop at university of Beni-Suef,2014.

2.                 Training on Internet Based Toefl cours,2013.

3.                 Training on Team Building of Team Leaders from DAAD organization at Beni-Suef University,2013.

4.                 Training on Self Marketing from DAAD organization at Beni-Suef University,2013 .

5.                 Training on Faculty and Leadership Developing Courses for improving the teaching capabilities at Beni-Suef University,2012 .

6.                  Attendance of international conference of Egypt Innovations at Beni-Suef University at March, 2015.

7.                  Attendance of a workshop about International Health Organization at Faculty of Pharmacy, Beni-Suef University on March,2015.

8.                  Attendance of a workshop about the description of the syllabus to be able to get the license of quality,December,2014.

9.                  Attendance of a seminar of How to increase the benefits from the scientififc data bases on eul, November 2014.

10.             Attendance of a lecture about the international agreements of Beni-Suef University with the other universities, 2014.

11.            Attendance in a seminar of the definition of DAA,2013..

12.            Attendance in a seminar of Masr Al Kheir for helping the researchers to get a scientific gran,2013.

13.            Attendances of the seminar of how to choose your scientific point hold by IRO at Beni-Suef University,2013.

14.            Attendance of the seminar of all what you need to know about the scientific grants at Beni-Suef University.

15.            Supervision of summer training of clinical pharmacy students at Hospital of Beni-Suef University,2012.

16.            Supervision of training of clinical pharmacy students at 57357 Hospital for 1 day,2010.

17.             Training as a community pharmacist for 7 months.

 

EXTRAS

1.     Excellent COMPUTER SKILLS in Microsoft package, Internet, E-mailing, Different Utility.

2.     Excellent command of ENGLISH “talking, Writing, Conducting Academic discussions.”

3.     Excellent Presentation & Communication skills.

4.     Accepting negative feedback in a constructive way to improve my Talents, Capabilities & Performance.

Energize others for best achievement of Team Objectives

Master Title

Effect of Antiepileptic drugs on liver enzymes

Master Abstract

Abstract Evidences reveal that antiepileptic drugs can alter liver enzymes leading to significant hepatotoxicity. Aim: To study the effect of antiepileptic drugs on liver enzymes as a side effect. Subjects and methods: This study was conducted on 49 patients with epilepsy (aged between 1 and 55 years) admitted to the neurology outpatient clinic at Beni Sueif University between February 2010 and June 2011. The patients were separated as group I (16 patients), treated with carbamazepine, 200-1200 mg /day; group II (16 patients), treated with sodium valproate, 200-800 mg/ day; and group III (17 patients), treated with phenytoin, 200-600 mg/ day. Serum liver enzymes aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and serum level of antiepileptic drug were determined. Results: Our results judged the presence of a statistically significant positive correlation between the dose/kg of Carbamazepine and the serum level of the drug, a statistically significant positive correlation between the dose/kg of Valproic acid and AST and a statistically significant negative correlation between the duration of administration of Valproic acid and AST. There is also a statistically significant negative correlation between the duration of administration of Carbamazepine and AST&ALP. Conclusion: The need for obtaining baseline liver function tests is essential before starting antiepileptic therapy and regular monitoring of serum aminotransferase values that had any of the risk factors for liver damage during antiepileptic therapy. Precautions should be taken when using antiepileptic drugs in epileptic patients with pre-existing hepatic disorders, in patients using potentially hepatotoxic drugs or if signs or symptoms of hepatic impairment appear. Because little long-term hepatic follow-up is available with antiepileptic treatment, controlled studies in larger samples should be carried out to reveal the frequency and the risk factors of serious hepatotoxicity.

PHD Title

Emitted dose and lung deposition from certain inhalation device

PHD Abstract

The main aim was to compare the efficiency of three different spacers with that of jet nebulizer through the measurement of in-vitro characteristics and the emitted dose of these inhalation devices in non-invasive ventilation (NIV) conditions and to use a urinary pharmacokinetic method to determine the relative lung and systemic bioavailability of inhaled salbutamol in NIV Chronic Obstructive Pulmonary disease (COPD) patients through the usage of high performance liquid chromatography (HPLC) with ultraviolet (UV) detector. Finally, a correlation between the in-vitro and in-vivo studies was conducted. Two new, accurate and sensitive HPLC methods for the determination of salbutamol in aqueous and urine samples were developed and validated. Salbutamol was extracted using solid phase extraction with bambeterol hydrochloride as internal standard. The accuracy, precision, lower limit of detection and recovery for both methods were within recognized limits. The in-vitro dose emission characteristics of salbutamol sulphate were measured using an Anderson Cascade Impactor (ACI) at a flow of 15 L/min. The total emitted dose (TED) and particle size distribution of salbutamol sulphate were determined with different spacers (AeroChamber MV, AeroChamber Vent and AeroChamber Mini spacers) and the jet nebulizer. The Mass median aerodynamic diameter (MMAD) of the spacers was the smallest (p=0.001) compared to that of the jet nebulizer. The TED deposited on the inhalation filter of the spacers used was about one third of that of the jet nebulizer. However the nominal dose placed into the nebulizer was about seven times that placed in the spacer. That resulted in an average of TED% from the spacer that was 2.5 fold that of the jet nebulizer. Twelve NIV COPD patients (6 females) with mean (SD) age and weight of 63.1(9.4) years, 70.3(8.5) kg respectively were included in this study. One dose of 1200 µg salbutamol in 12 puffs of salbutamol MDI attached to one of the previously described three spacers fitted from one side to the continuous positive airway pressure (CPAP) as non-invasive ventilator and the other side was sealed to the facemask of the patient and amounts of urinary salbutamol excreted 0.5 and 24 hour post dosing were measured. The mean (SD) salbutamol excreted in 30 minute period after the start inhalation of the study dose from the AeroChamber MV, the AeroChamber Vent and the AeroChamber Mini spacers were 54.29(23.68), 44.42(21.55) and 50.42(23.27) µg, respectively and the mean (SD) 24 hours urinary excretion were 295.93 (176.37), 353.55 (131.23) and 363.82(162) µg, respectively. This urinary pharmacokinetic method to identity relative lung and systemic bioavailability between three spacer devices was easy to perform and is a useful and simple in-vivo method to compare the drug delivering efficiency of different spacers in patients receiving non-invasive ventilation. Data mining technology based on artificial neural networks and genetic algorithms were used to model the in-vitro inhalation process, predict and optimize bioavailability from the inhaled doses delivered by MDI using three different spacers in NIV. The modeling of the data indicated that the in-vitro performance of the MDI-spacer systems was dependent mainly on FPD, FPF, MMAD and to lesser extent on the spacer type. The ex-vivo model indicated that the amount of salbutamol collected on the face mask filter was directly affected by FPF and inversely affected by total emitted dose (TED; In-vitro inhalation filter). The in-vivo model (24 h Q) depended directly on the increasing levels of both FPF and TED. Also the female patients showed higher 0.5 h and 24 h Q values than males, whilst spacer type AeroChamber VC demonstrated higher in-vitro TED and resulted also in higher 24 h Q in-vivo values.